Kornimate/medical-research-clean huggingface dataset:
study comparing inhaled amikacin versus placebo to prevent ventilator associated pneumonia

Conditions: Pneumonia, Ventilator-Associated

Summary: the objective of the study is to prove that after the third day of invasive mechanical ventilation a three-day course of inhaled amikacin reduces the incidence of subsequent vap. parallel two group double blind randomized controlled clinical trial. individual randomization, performed on day 4 of invasive mechanical ventilation, will be stratified on centre in order to account for variations in vap prevention bundle implementation and use of systemic antibiotics the day of randomization. patients will be treated three consecutive days with inhaled amikacin or placebo. patients will be followed up daily in the intensive care unit for the occurrence of vap according to international guidelines until day 28.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years the day of inclusion * mechanical ventilation through an endotracheal tube for more than three consecutive days (72h) * written informed consent of the patient or a proxy * patients covered by or having the rights to french social security * negative pregnancy test, at the time of inclusion, in women of childbearing potential exclusion criteria: * suspicion or confirmed vap the day of inclusion * clinical indication for systemic aminoglycoside therapy the day of inclusion : as deemed necessary by the clinician in charge * stage 2 or 3 kdigo\* classification acute kidney injury the day of inclusion excepted in patients undergoing renal replacement therapy * chronic kidney failure : baseline glomerular filtration lower than 30 ml/min * patient scheduled for extubation within the next 24h * patient ventilated through an endotracheal tube for more than four consecutive days before inclusion (96h) * patient ventilated through a tracheostomy * patients allergic to aminoglycosides * myasthenia gravis * known pregnant women at the time of inclusion and lactating patients * known guardianship or trusteeship at the time of inclusion * patients previously included in this study

Keywords: prevention inhaled amikacin placebo
reliability and validity studies of turkish version of manual ability measure-36

Conditions: Parkinson Disease; Multiple Sclerosis; Stroke; Upper Extremity Problem

Summary: this study aim was to investigate the validity and reliability of turkish version of manual ability measure-36 (mam-36) in patients with neurological disease.

the reliability and validity of the scale were initiated by language equivalence and cultural adaptation. the mam-36 scale was translated into turkish by two experienced physiotherapists who are native turkish speakers and have a good command of english, following the translation procedures. the two translations were compared with each other and a single turkish draft was created. this draft was translated back into english by two translators who are native english speakers and have a good command of turkish. the two back translations were compared to each other and converted into a single form. the resulting form was compared with the original form and the final back-translation scale was created. all translation formats of the scale were examined in detail by those who translated the scale into turkish and a jury consisting of experienced physiotherapists. at the end of the meeting, the pilot study form of the scale was created. the created draft was applied to 30 healthy individuals as a pilot study. the final version of the scale was created by evaluating the feedback obtained. the clinical phase of the study was carried out on 250 volunteer individuals who applied to dokuz eylül university hospital neurology department polyclinics and were diagnosed with ms, parkinson's disease, and stroke, and who had various degrees of problems in hand dexterity and functions due to their diseases. to evaluate the validity of mam-36, disability of arm shoulder and hand (dash), which can measure manual dexterity and was validated in turkish, was used. the scales were repeated 15 days later to assess test-retest reliability.

Eligibility criteria:
inclusion criteria: * being diagnosed with a neurological disease (stroke, parkinson's or ms) * at least one upper extremity is affected * being conscious enough to complete the survey and knowing how to read and write * agreeing to participate in the research * being over 18 years old exclusion criteria: * having an upper extremity operation within the last 6 months * having had an attack or seizure in the last month * participating in any physical therapy program during the study
chicken model in teaching episiotomy repair

Conditions: Episiotomy Wound

Summary: the aim of this study is to determine the effect of chicken use in episiotomy repair training of midwifery students on students' satisfaction, self-confidence and anxiety levels. hypotheses h01 there is no difference between the satisfaction score of the chicken group and the satisfaction score of the control group in episiotomy repair training. h02 in episiotomy repair training, there is no difference between the self-confidence score of the chicken group and the self-confidence score of the control group. h03 there is no difference between the anxiety score of the chicken group and the anxiety score of the control group in episiotomy repair training.


Eligibility criteria:
inclusion criteria: * midwifery students who were registered in the midwifery department in the 2020-2021 academic year and take childbearing course, * students over the age of 18 exclusion criteria: * having previously received training on episiotomy and its repair, * students who fill in the data collection forms incompletely will not be included in the study.
safety, tolerability, pk & pd of ab-101 following oral administration in healthy and chb subjects.

Conditions: Chronic Hepatitis B

Summary: this three-part, phase 1 protocol will be the first clinical study of ab-101. parts 1 and 2 will be a phase 1a sad/mad of ab-101 in healthy adult subjects. part 3 will be a phase 1b dose-ranging assessment of ab-101 in non-cirrhotic chronic hepatitis b (chb) subjects.


Eligibility criteria:
inclusion criteria: part 1 and 2 (healthy volunteers) * male between ages 18-50 years * willing and able to provide informed consent willing to follow protocol-specified contraception requirement inclusion criteria: part 3 (chb subjects) * male or female subjects between the ages of 18-60 years * willing to provide informed consent * chronic hbv infection for at least 6 months * willing to follow protocol-specified contraception requirement exclusion criteria: part 1 and 2 (healthy volunteers) key exclusion criteria: * clinically significant lab abnormalities * a history of clinically significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, autoimmune or other immune-mediated disease. * hiv or hep c positive * known chronic or severe infection or recent significant exposure to infections such as tuberculosis or endemic mycosis, untreated latent infections like tuberculosis, or a positive or indeterminate quantiferon test. exclusion criteria: part 3 (chb subjects) * have extensive fibrosis or cirrhosis of the liver * have or had liver cancer (hepatocellular carcinoma) * have a history or current autoimmune disease or has been on immunosuppressive medications within 6 months of the start of the study * females who breastfeeding, pregnant or who wish to become pregnant during the study * known chronic or severe infection or recent significant exposure to infections such as tuberculosis or endemic mycosis, untreated latent infections like tuberculosis, or a positive or indeterminate quantiferon test.
sensitivity of basic taste in elderly

Conditions: Taste Disorders

Summary: the purpose of this study is to identify the thresholds sensitivity of the five basic tastes in an elderly population and relate to food intake, nutritional status, age, gender and others variables.

the investigators propose a study of 300 elderly patients to characterize de sensitivity of the four basic tastes, according to the methodology of international organization for standardization (1985) and to identify umami taste (mojet et al. 2001, 2003). this is a cross-sectional study. the length of the inclusion of the study will be 24 months. this study's general objective is: to characterize food intake, nutritional status and identify thresholds for the five basic tastes in an elderly population.

Eligibility criteria:
inclusion criteria: * 60 years old patient or older, who present oral feeding and the ability to express themselves to perform the sensory analysis tests will be included. exclusion criteria: * patient with fever, flu, cold or some complication in the oral cavity will be excluded, since these factors can interfere in the perception of the tastes and those that do not present conditions to express themselves or deficits of cognition, being excluded the elderly that present result of the application of the mini mental under 24. in addition to those who do not agree to sign the term of free and informed consent.

Keywords: elderly taste thresholds
idiotypic vaccination for follicular lymphoma patients

Conditions: Follicular Lymphoma; First Relapse/Progression

Summary: poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6 years. the proposed trial offers life-time idiotypic vaccination to all such patients in first relapse/progression who will achieve second (first, in the case of patients who have never achieved complete response following standard first-line treatment) complete response through autologous stem cell transplant prior to vaccination start. the ultimate goal is a cure, defined as a vaccine-maintained complete response lasting both at least 10 years and at least twice as long as each patient's first complete response.

idiotypic vaccination has already proved capable (in responding patients) of: biological efficacy, that is the capacity of inducing an idiotype- and tumor-specific immune response (kwak lw et al. nejm 1992); clinical efficacy, that is the capacity of inducing specific immune responses able to kill in vivo follicular lymphoma cells that had survived pre-vaccine chemotherapy (bendandi m et al. nature med 1999): clinical benefit, that is the capacity of prolonging survival of responding patients (inoges et al. jnci 2006). now, we want to test whether it is also capable of contributing to the ultimate goal of preventing relapse indefinitely in responding patients.

Eligibility criteria:
inclusion criteria: at least one of the following: * flipi score 3 thru 5 at diagnosis and/or at relapse * first complete response shorter than 3 years, if no maintenance (interferon, rituximab, etc) treatment was administered, or than 5 years if maintenance treatment was administered * no treatment has been able to induce complete response until autologous stem cell transplant * poor-prognosis genomic profiling exclusion criteria: any of the following: * unavailability of a harvestable lymph node of at least cm 2x2x2 * life expectancy \< 1 year * abnormal heart or liver or kidney function * ecog performance status \> 2 * failure to sign informed consent before enrollment

Keywords: follicular lymphoma idiotype vaccine
duration of dual antiretroviral therapy in virologically suppressed people living with hiv and factors associated with switching to tritherapy : a real-life cohort

Conditions: HIV Infections

Summary: hiv infection requires lifelong continuous antiretroviral (arv) treatment. the efficacy of current arv treatments makes it possible to propose strategies for reducing the cumulative exposure to arvs, side effects and costs. and so improve the quality of life of people living with hiv (plhiv). however, in the real world, less regular adherence to treatment, more heavily pre-treated patients and resistance to treatment make these dual therapies prescribed beyond the strict framework of clinical trials. this can lead to undesirable side effects. from the perspective of personalized medicine, it seems to be important to determine which patients are receiving dual arv therapy, and which patients remain on it for a long time. identifying prognostic factors would enable us to adapt therapeutic management.


Eligibility criteria:
inclusion criteria: * hiv patient * viral load \< 50copies/ml * patient treated with dual therapy * patients with hospital follow-up between 2011 and 2023 exclusion criteria: * adults under legal protection * underage

Keywords: epidemiology
cerviprep for applying topical gemcitabine to the cervix in treating patients with primary endometrial, cervical, or ovarian epithelial cancer

Conditions: Cervical Cancer; Endometrial Cancer; Ovarian Cancer

Summary: rationale: drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. using the cerviprep™ drug delivery device to apply topical gemcitabine to the cervix may be an effective way to kill more tumor cells. purpose: this phase ii trial is studying how well cerviprep™ works in applying topical gemcitabine to the cervix in treating patients with primary endometrial cancer, cervical cancer, or ovarian epithelial cancer.

objectives: primary * to evaluate the efficacy of the cerviprep™ device in delivering topical gemcitabine hydrochloride to the cervix secondary * to document any side effects directly attributed to local administration of gemcitabine hydrochloride. outline: patients undergo application of topical gemcitabine hydrochloride directly to the cervix using the cerviprep™ drug delivery device during routine hysterectomy. uterine vein and peripheral blood samples are obtained periodically to measure local and peripheral gemcitabine hydrochloride concentration levels in the blood. local gemcitabine hydrochloride concentration levels are also measured in uterine tissue samples obtained from the surgical specimen after hysterectomy. patients complete a self-reported symptom diary for the first 7 days after surgery for assessment of local and systemic side effects associated with topical administration of gemcitabine hydrochloride. after completion of study therapy, patients are followed at 2-4 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of primary endometrial or cervical cancer * scheduled to undergo abdominal hysterectomy as part of surgical staging and/or treatment * gynecologic oncology group (gog) performance status 0-2 * absolute neutrophil count (anc) ≥ 1,500 cells/mm³ * platelet count ≥ 100,000 cells/mm³ * creatinine ≤ 2.5 mg/dl * serum aspartate aminotransferase (ast) or alanine transaminase (alt) ≤ 3 times upper limit of normal * total bilirubin ≤ 2.0 mg/dl * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception exclusion criteria: * serious medical condition or psychiatric illness that places the patient at an unacceptable risk for study participation or precludes signing the informed consent * known allergic reaction or hypersensitivity to gemcitabine hydrochloride * prior radiotherapy to the whole abdomen or pelvis * more than 28 days since prior standard or experimental anticancer therapy * no other concurrent anticancer agents

Keywords: recurrent cervical cancer cervical cancer endometrial carcinoma ovarian epithelial cancer recurrent ovarian epithelial cancer recurrent endometrial carcinoma
a lifestyle change program to prevent type 2 diabetes

Conditions: Prediabetes

Summary: the purpose of this study was to evaluate the effect of a diabetes prevention program provided by nurse practitioners in primary care to adults at risk for diabetes.


Eligibility criteria:
inclusion criteria * age 21 or older * medically stable and safe to exercise * at high risk for type 2 diabetes * able to speak english. exclusion criteria * type 2 diabetes * cardiovascular disease * cancer requiring treatment in the past 5 years * anemia * hepatitis * renal disease * gastrointestinal disease * recent or significant abdominal surgery * pulmonary disease with dependence on oxygen or daily use of bronchodilators * chronic infection (ie., hiv, active tuberculosis) * unable to walk 0.25 miles in 10 minutes * participation in commercial diet program * currently pregnant or within 3 months postpartum * currently nursing or within 6 weeks of having completed nursing * treatment of impaired glucose tolerance (igt) with metformin * currently taking any glucocorticoid or beta-blocker * recently prescribed or changed dose of a statin (within 2 months)

Keywords: diabetes prevention, primary care
analysis of the relevance of radiologic parameters on the outcome after hip arthroscopy

Conditions: Femoro-acetabular Impingement; Hip Impingement Syndrome; Hip Disease

Summary: joint-preserving surgery with arthroscopic techniques of the hip follows detailed radiological assessment including plain radiography of the hips and magnetic resonance arthrography (mri). the purpose of this study was to compare features on radiography and mri of the hip before surgery and assess their prognostic value on the outcome after surgery.

hip arthroscopy is indicated for the treatment of a variety of pathologies of the hip, in patients without osteoarthritis. the diagnosis in patients with pain at the hip is made after history taking, clinical examination and radiological evaluation with plain radiography in a standardized technique and a magnetic resonance arthrography of the hip. the main indications for hip arthroscopy include cam-type femoroacetabular impingement (fai) necessitating bony decompression and chondro-labral tears necessitating arthroscopic repair or debridement. the purpose of this radiological non-interventional outcome study was to assess features on plain radiography and mri in favor of good outcome after hip arthroscopy. this department performed 810 hip arthroscopies in the years of 2013 till 2021. all of those patients underwent standardized radiological evaluation with radiography and mri. radiographical parameters are assessed by a resident with experience in musculo-sceletal radiology, intra- and inter-observer reliability has been assessed for each parameter. all arthroscopies have been performed by two experience senior orthopedic surgeons. ethical board approval has been obtained to follow-up on those patients. follow-up includes the patient-reported outcome assessment using the ihot12 score and the modified harris hip score. the clinical end-point is the time till total hip arthroplasty (tha), a registry analysis of the tyrolean arthroplasty registry (tar) has been performed. statistical analysis is performed using anova and fishers t-tests, the level of significance is .05.

Eligibility criteria:
inclusion criteria: * hip arthroscopy from 2013-2021 at this department. exclusion criteria: * age below 18 years.

Keywords: magnetic resonance arthrography hip arthroscopy
metformin and folate in pregnant polycystic ovary syndrome(pcos) women

Conditions: Pregnancy; Polycystic Ovary Syndrome

Summary: a more recent prospective nonrandomized placebo-controlled double-blind clinical study demonstrated that metformin exerts a slight but significant deleterious effect on serum homocysteine (hcy) levels in patients with pcos, and supplementation with folate is useful to increase the beneficial effect of metformin on the vascular endothelium.

pcos (cases) and non-pcos (controls) pregnant women were enrolled. cases will be randomized in four treatment groups: metformin plus placebo (group a1), metformin plus folic acid (group a2), placebo plus folic acid (group a3), placebo alone (group a4). controls will not received any treatment (group b). clinical and biochemical assessment (including serum markers of implantation), doppler velocimetry of the uterine arteries, and trophoblastic invasion at histological and immunohistochemical evaluation. changes in clinical and biochemical data under treatment, pattern of doppler velocimetry at the uterine arteries, and trophoblastic invasion were evaluated.

Eligibility criteria:
inclusion criteria: * pregnancy * pcos exclusion criteria: * risk factors for pregnancy complications * severe obesity

Keywords: folate metformin pcos pregnancy trophoblastic invasion uterine artery velocimetry
treatment of patients with the obstructive sleep apnea syndrome at altitude

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the purpose of the study is to investigate the effect of acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude


Eligibility criteria:
inclusion criteria: * obstructive sleep apnea syndrome, successfully on cpap therapy * residence at low altitude (\<800m) * obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of cpap therapy. * \>15 oxygen desaturations/h (\>3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without cpap exclusion criteria: * sleep disorders other than osa. * more than mild cardiovascular disease, unstable or recently diagnosed (within the last 6 months) cardiovascular disease such as arterial hypertension, coronary artery or cerebrovascular disease. * any lung disease, pulmonary hypertension. * chronic rhinitis. * treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline) * internal, neurologic or psychiatric disease that interfere with sleep quality. * previous intolerance to moderate or low altitude (\<2600m). * exposure to altitudes \>1500m for \>1 day within the last 4 weeks before the study

Keywords: apnea, sleep, altitude, hypoxia